HopeStage
Back to all studies
Active Not RecruitingNCT05333003

Semaglutide for weight management in people with schizophrenia and obesity

About this titleRead the official source — NCT05333003
Medication studyAges 18–70Canada
The study in practice

Understand this study

Who could participate?

Listed age limits: 18 years to 70 years.

Listed locations
TorontoSee all locations and recruitment

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: May 25, 2022
Recruitment status
Active Not Recruiting
Enrollment listed in the registry
92
Sponsor
Centre for Addiction and Mental Health
Sponsor type
Hospital / academic medical center
Study type
Drug
Intervention type
Drug, Other
Locations
Canada
Age range
From 18 Years to 70 Years
Official registry ID
NCT05333003
Official title
Show the full official title

Semaglutide in Comorbid Schizophrenia Spectrum Disorder and Obesity for Metformin Non-responders: a Single-blind Randomized Control Trial

Recruitment & locations

Not recruiting

Toronto

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Centre for Addiction and Mental Health, a hospital or academic medical center.

Does this study involve medication?

Yes. The study involves medication, including Semaglutide.

Who can participate?

Listed age limits: 18 years to 70 years.

Is this study still recruiting?

The registry lists this study as active, but no longer recruiting.

Want to explore more studies?

Explore studies